Theracryf Plc (FRA:8EV)
Germany
· Delayed Price · Currency is EUR 0.0005
0.00 (0.00%)
At close: Dec 5, 2025
Theracryf Statistics
Total Valuation
Theracryf has a market cap or net worth of EUR 5.17 million. The enterprise value is 1.16 million.
| Market Cap | 5.17M |
| Enterprise Value | 1.16M |
Important Dates
The last earnings date was Wednesday, December 3, 2025.
| Earnings Date | Dec 3, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 2.15B |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +300.38% |
| Shares Change (QoQ) | +228.79% |
| Owned by Insiders (%) | 28.74% |
| Owned by Institutions (%) | 56.10% |
| Float | 1.25B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 0.94 |
| P/TBV Ratio | 1.92 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.51 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.29
| Current Ratio | 2.29 |
| Quick Ratio | 2.29 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -53.79% and return on invested capital (ROIC) is -37.57%.
| Return on Equity (ROE) | -53.79% |
| Return on Assets (ROA) | -28.77% |
| Return on Invested Capital (ROIC) | -37.57% |
| Return on Capital Employed (ROCE) | -46.75% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -255,736 |
| Employee Count | 9 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -164,975 |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Relative Strength Index (RSI) | 48.15 |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | -2.56M |
| Operating Income | -2.57M |
| Pretax Income | -2.47M |
| Net Income | -2.30M |
| EBITDA | -2.53M |
| EBIT | -2.57M |
| Earnings Per Share (EPS) | -0.00 |
Balance Sheet
The company has 4.01 million in cash and n/a in debt, giving a net cash position of 4.01 million.
| Cash & Cash Equivalents | 4.01M |
| Total Debt | n/a |
| Net Cash | 4.01M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 5.50M |
| Book Value Per Share | 0.00 |
| Working Capital | 2.69M |
Cash Flow
| Operating Cash Flow | -1.95M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Theracryf does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -300.38% |
| Shareholder Yield | -300.38% |
| Earnings Yield | -44.53% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |